Elshinshawy Sarah, Elhaddad Hemmat, Abdel Alem Shereen, Shaker Olfat, Salam Randa, Yosry Ayman, Elebrashy Ibrahim
Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt.
Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt.
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):638-648. doi: 10.1016/j.jceh.2023.03.004. Epub 2023 Mar 16.
Thyroid hormones play an important role in the regulation of diverse metabolic processes and might play a crucial role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, their association remains controversial. Therefore, our aim is to clarify whether overt or subclinical hypothyroidism was associated with NAFLD.
This cross-sectional study included 60 participants with a new diagnosis of hypothyroidism and 30 age- and gender-matched healthy participants with thyroid-stimulating hormone (TSH) level <4.5 mIU/L. Anthropometric measurements, laboratory parameters, plasma fibroblast growth factor 21 (FGF21), and hepatic steatosis diagnosed via controlled attenuation parameter (CAP) using transient elastography between the hypothyroid groups and control group were analyzed.
Participants with hypothyroidism displayed significantly higher serum aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, total cholestrol, triglycerides, low-density lipoprotein cholesterol, TSH, hemoglobin A1c, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) but significantly lower serum albumin, high-density lipoprotein cholesterol, and free thyroxine levels than the control group ( = <0.001). The CAP values were significantly higher in participants with overt and subclinical hypothyroidism than the control group ( = <0.001). The only significant independent predictors of steatosis in our study were free T4, body mass index, and HOMA-IR after using multivariate logistic regression. The mean serum FGF21 levels were increased in hypothyroid participants with hepatic steatosis than those without hepatic steatosis (126.9 ± 272.6) pg/ml vs. (106.8 ± 138.7) pg/ml, = 0.8). Receiver operating characteristic (ROC) curve showed that FGF21 was not a significant marker for hepatic steatosis in hypothyroid participants (area under curve (AUC) = 0.44, = 0.54).
Individuals with subclinical or overt hypothyroidism were more likely to have NAFLD than those with normal thyroid function. Serum FGF21 levels were increased in hypothyroid individuals and its role as a marker of hepatic steatosis in hypothyroid individuals needs further assessment.
甲状腺激素在多种代谢过程的调节中发挥重要作用,可能在非酒精性脂肪性肝病(NAFLD)的发病机制中起关键作用。然而,它们之间的关联仍存在争议。因此,我们的目的是阐明显性或亚临床甲状腺功能减退是否与NAFLD相关。
这项横断面研究纳入了60名新诊断为甲状腺功能减退的参与者和30名年龄及性别匹配、促甲状腺激素(TSH)水平<4.5 mIU/L的健康参与者。分析了甲状腺功能减退组和对照组之间的人体测量指标、实验室参数、血浆成纤维细胞生长因子21(FGF21)以及通过瞬时弹性成像使用受控衰减参数(CAP)诊断的肝脂肪变性情况。
与对照组相比,甲状腺功能减退的参与者血清天冬氨酸氨基转移酶、丙氨酸氨基转移酶、γ-谷氨酰转移酶、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、TSH、糖化血红蛋白、空腹胰岛素以及胰岛素抵抗稳态模型评估(HOMA-IR)显著更高,但血清白蛋白、高密度脂蛋白胆固醇和游离甲状腺素水平显著更低(P<0.001)。显性和亚临床甲状腺功能减退参与者的CAP值显著高于对照组(P<0.001)。在我们的研究中,使用多因素逻辑回归后,肝脂肪变性的唯一显著独立预测因素是游离T4、体重指数和HOMA-IR。与无肝脂肪变性的甲状腺功能减退参与者相比,有肝脂肪变性的甲状腺功能减退参与者的平均血清FGF21水平升高(126.9±272.6)pg/ml对(106.8±138.7)pg/ml,P = 0.8)。受试者工作特征(ROC)曲线显示,FGF21在甲状腺功能减退参与者中不是肝脂肪变性的显著标志物(曲线下面积(AUC)= 0.44,P = 0.54)。
与甲状腺功能正常的个体相比,亚临床或显性甲状腺功能减退的个体更易患NAFLD。甲状腺功能减退个体的血清FGF21水平升高,其作为甲状腺功能减退个体肝脂肪变性标志物的作用需要进一步评估。